CO6300953A2 - Antagonistas del receptor mineralcorticoide y metodos de uso - Google Patents
Antagonistas del receptor mineralcorticoide y metodos de usoInfo
- Publication number
- CO6300953A2 CO6300953A2 CO10072532A CO10072532A CO6300953A2 CO 6300953 A2 CO6300953 A2 CO 6300953A2 CO 10072532 A CO10072532 A CO 10072532A CO 10072532 A CO10072532 A CO 10072532A CO 6300953 A2 CO6300953 A2 CO 6300953A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- compound
- formula
- mineralcorticoid
- pharmaceutically acceptable
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 239000002395 mineralocorticoid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 208000033679 diabetic kidney disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1477607P | 2007-12-19 | 2007-12-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6300953A2 true CO6300953A2 (es) | 2011-07-21 |
Family
ID=40430143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10072532A CO6300953A2 (es) | 2007-12-19 | 2010-06-16 | Antagonistas del receptor mineralcorticoide y metodos de uso |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US7994164B2 (https=) |
| EP (2) | EP2235007B1 (https=) |
| JP (1) | JP5562866B2 (https=) |
| KR (1) | KR101254382B1 (https=) |
| CN (1) | CN101903377B (https=) |
| AR (1) | AR069554A1 (https=) |
| AU (1) | AU2008343524B2 (https=) |
| BR (1) | BRPI0820805A2 (https=) |
| CA (1) | CA2710409C (https=) |
| CL (1) | CL2008003600A1 (https=) |
| CO (1) | CO6300953A2 (https=) |
| DK (1) | DK2235007T3 (https=) |
| DO (1) | DOP2010000185A (https=) |
| EA (1) | EA017668B1 (https=) |
| EC (2) | ECSP10010266A (https=) |
| ES (2) | ES2459318T3 (https=) |
| GT (1) | GT201000179A (https=) |
| HR (1) | HRP20120916T1 (https=) |
| IL (1) | IL206353A (https=) |
| MA (1) | MA31910B1 (https=) |
| MX (1) | MX2010006911A (https=) |
| MY (1) | MY150474A (https=) |
| NZ (1) | NZ586300A (https=) |
| PE (1) | PE20091057A1 (https=) |
| PL (1) | PL2235007T3 (https=) |
| PT (1) | PT2235007E (https=) |
| RS (1) | RS52594B (https=) |
| SI (1) | SI2235007T1 (https=) |
| TN (1) | TN2010000292A1 (https=) |
| TW (1) | TWI431010B (https=) |
| UA (1) | UA100131C2 (https=) |
| WO (1) | WO2009085584A1 (https=) |
| ZA (1) | ZA201004257B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8242140B2 (en) | 2007-08-03 | 2012-08-14 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| EP2234977A4 (en) | 2007-12-19 | 2011-04-13 | Boehringer Ingelheim Int | VIRAL POLYMERASE INHIBITORS |
| AU2010222902B2 (en) * | 2009-03-12 | 2013-04-18 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
| EP2977084B1 (en) | 2010-05-10 | 2017-07-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina |
| JP6180930B2 (ja) | 2010-06-16 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 創傷治癒過程における再上皮化を刺激するための方法及び組成物 |
| CN102060670A (zh) * | 2011-01-04 | 2011-05-18 | 常州大学 | 一种2-溴-6-氟苯甲醇的制备方法 |
| AU2014261070A1 (en) | 2013-05-02 | 2015-10-29 | Pfizer Inc. | Imidazo-triazine derivatives as PDE10 inhibitors |
| AR099416A1 (es) | 2014-02-28 | 2016-07-20 | Lilly Co Eli | Terapia combinada para la hipertensión resistente |
| MX367404B (es) | 2014-06-30 | 2019-08-20 | Astrazeneca Ab | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. |
| US20170246166A1 (en) * | 2014-11-21 | 2017-08-31 | Eli Lilly And Company | 1,2-benzothiazole compounds for the treatment of kidney disorders |
| JP6835836B2 (ja) | 2015-10-13 | 2021-02-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 脈絡膜血管新生の処置のための方法及び医薬組成物 |
| EP3490606B8 (en) | 2016-07-26 | 2024-04-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis |
| RU2725153C1 (ru) * | 2016-09-24 | 2020-06-30 | Кбп Биосаенсес Ко., Лтд | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение |
| JP7697961B2 (ja) | 2020-03-11 | 2025-06-24 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。 |
| US20240366632A1 (en) | 2021-08-31 | 2024-11-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of ocular rosacea |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4072756A (en) * | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
| SE426341C (sv) * | 1980-02-14 | 1985-09-23 | Fagersta Ab | Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser |
| DE3730258A1 (de) * | 1986-09-10 | 1988-04-07 | Canon Kk | Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung |
| CA1338625C (en) * | 1988-06-09 | 1996-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Tricyclic compounds |
| GB8914061D0 (en) * | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| US5378701A (en) * | 1991-12-27 | 1995-01-03 | Kyowa Hakko Kogyo | Tricyclic compounds |
| AR014195A1 (es) | 1997-12-29 | 2001-02-07 | Ortho Mcneil Pharm Inc | Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos |
| US7056911B1 (en) | 1999-01-26 | 2006-06-06 | Dana-Farber Cancer Institute | Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof |
| NZ596484A (en) * | 2001-11-21 | 2013-05-31 | Millennium Pharm Inc | Chemokine receptor antagonists and methods of use thereof |
| TW200400816A (en) * | 2002-06-26 | 2004-01-16 | Lilly Co Eli | Tricyclic steroid hormone nuclear receptor modulators |
| US7482344B2 (en) * | 2003-12-19 | 2009-01-27 | Eli Lilly And Company | Tricyclic steroid hormone nuclear receptor modulators |
| CN1918151A (zh) * | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| RU2007107177A (ru) | 2004-07-28 | 2008-09-10 | Айрм Ллк (Bm) | Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов |
| CA2585797C (en) | 2004-11-10 | 2015-01-06 | Incyte Corporation | Lactam compounds and their use as pharmaceuticals |
| SI2089367T1 (sl) | 2006-10-31 | 2012-02-29 | Pfizer Prod Inc | Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev |
| JP2010522732A (ja) | 2007-03-29 | 2010-07-08 | ナームローゼ・フエンノートチヤツプ・オルガノン | 鉱質コルチコイド受容体アンタゴニスト |
| GB0725102D0 (en) | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
| PE20091339A1 (es) | 2007-12-21 | 2009-09-26 | Glaxo Group Ltd | Derivados de oxadiazol con actividad sobre receptores s1p1 |
| AU2009206733A1 (en) | 2008-01-25 | 2009-07-30 | Arena Pharmaceuticals, Inc. | Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists |
| AU2010222902B2 (en) | 2009-03-12 | 2013-04-18 | Eli Lilly And Company | Mineralocorticoid receptor antagonist and methods of use |
-
2008
- 2008-12-02 TW TW097146779A patent/TWI431010B/zh not_active IP Right Cessation
- 2008-12-02 PE PE2008002008A patent/PE20091057A1/es not_active Application Discontinuation
- 2008-12-03 CL CL2008003600A patent/CL2008003600A1/es unknown
- 2008-12-03 AR ARP080105263A patent/AR069554A1/es unknown
- 2008-12-09 EA EA201070762A patent/EA017668B1/ru not_active IP Right Cessation
- 2008-12-09 MY MYPI20102867 patent/MY150474A/en unknown
- 2008-12-09 AU AU2008343524A patent/AU2008343524B2/en not_active Ceased
- 2008-12-09 PT PT88668355T patent/PT2235007E/pt unknown
- 2008-12-09 ES ES12185389.9T patent/ES2459318T3/es active Active
- 2008-12-09 BR BRPI0820805-0A patent/BRPI0820805A2/pt not_active IP Right Cessation
- 2008-12-09 CA CA2710409A patent/CA2710409C/en not_active Expired - Fee Related
- 2008-12-09 UA UAA201007627A patent/UA100131C2/uk unknown
- 2008-12-09 NZ NZ586300A patent/NZ586300A/en not_active IP Right Cessation
- 2008-12-09 HR HRP20120916AT patent/HRP20120916T1/hr unknown
- 2008-12-09 CN CN200880121527.2A patent/CN101903377B/zh not_active Expired - Fee Related
- 2008-12-09 ES ES08866835T patent/ES2396605T3/es active Active
- 2008-12-09 EP EP08866835A patent/EP2235007B1/en active Active
- 2008-12-09 DK DK08866835.5T patent/DK2235007T3/da active
- 2008-12-09 SI SI200830852T patent/SI2235007T1/sl unknown
- 2008-12-09 US US12/330,539 patent/US7994164B2/en not_active Expired - Fee Related
- 2008-12-09 JP JP2010539618A patent/JP5562866B2/ja not_active Expired - Fee Related
- 2008-12-09 MX MX2010006911A patent/MX2010006911A/es active IP Right Grant
- 2008-12-09 WO PCT/US2008/085997 patent/WO2009085584A1/en not_active Ceased
- 2008-12-09 KR KR1020107013601A patent/KR101254382B1/ko not_active Expired - Fee Related
- 2008-12-09 RS RS20120541A patent/RS52594B/sr unknown
- 2008-12-09 EP EP12185389.9A patent/EP2537845B1/en active Active
- 2008-12-09 PL PL08866835T patent/PL2235007T3/pl unknown
-
2010
- 2010-06-14 MA MA32909A patent/MA31910B1/fr unknown
- 2010-06-14 IL IL206353A patent/IL206353A/en not_active IP Right Cessation
- 2010-06-15 ZA ZA2010/04257A patent/ZA201004257B/en unknown
- 2010-06-16 CO CO10072532A patent/CO6300953A2/es not_active Application Discontinuation
- 2010-06-17 EC EC2010010266A patent/ECSP10010266A/es unknown
- 2010-06-17 GT GT201000179A patent/GT201000179A/es unknown
- 2010-06-17 DO DO2010000185A patent/DOP2010000185A/es unknown
- 2010-06-18 TN TN2010000292A patent/TN2010000292A1/fr unknown
-
2012
- 2012-07-17 EC ECSP12012048 patent/ECSP12012048A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6300953A2 (es) | Antagonistas del receptor mineralcorticoide y metodos de uso | |
| PE20221914A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
| CL2011002989A1 (es) | Compuestos heterociclicos inhibidores de la endopeptidasa neutra (nep); composicion farmaceutica; combinacion farmaceutica; uso del compuesto patra tratar un trastorno o enfermedad tal como hipertencion, insuficiencia cardiaca, insuficiencia renal, epilepsia, sindrome metabolico, entre otros. | |
| CR9304A (es) | Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| MX2009006795A (es) | Compuestos que tienen tanto actividades de antagonismo de receptor de angiotensina ii como actividades activadoras de receptores activados por proliferizador de peroxisomas gamma. | |
| UY32062A (es) | Inhibidores de beta-secretasa | |
| WO2009054423A1 (ja) | オキサジアゾリジンジオン化合物 | |
| EA201000211A1 (ru) | Способ модулирования рецептора gpr119, сопряженного с g-белком, и используемые при этом соединения | |
| CL2011001848A1 (es) | Compuestos derivados de pirimidina fusionada a un heterociclo de 5 miembros; antagonista del receptor de angiotensina ii, agonista del receptor de proliferador de peroxisomas; composicion farmaceutica; y uso de los compuestos en el tratamiento de enfermedades circulatorias tales como hipertension, enfermedad cardiaca, arteriosclerosis, entre otras. | |
| MX336881B (es) | Compuestos heterociclicos triciclicos. | |
| CY1110922T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| AR124688A2 (es) | Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo | |
| MX2009000169A (es) | Derivados de purinona como agonistas de hm74a. | |
| CO2021016870A2 (es) | Compuestos de pirazol disustituidos como inhibidores de cetohexoquinasa | |
| WO2007120270A3 (en) | Glucagon receptor antagonists, preparation and therapeutic uses | |
| CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
| WO2009018226A3 (en) | Pharmaceutical combinations comprising a tyrosine kinase inhibitor and an antibody against integrin alpha 1 beta 5 (cd49e) | |
| EA201171125A1 (ru) | Антагонист минералокортикоидного рецептора и способы его применения | |
| DK1951659T3 (da) | Glucagonreceptorantagonister, fremstilling og terapeutisk anvendelse heraf | |
| MX2012015112A (es) | Uso de antagonistas del receptor de adenosina a2b para el tratamiento de la hipertension pulmonar. | |
| WO2012163088A3 (zh) | 肾病和心脏病的治疗药物及其用途 | |
| CR11471A (es) | Antagonista del receptor mineralcorticoide y metodos de uso | |
| JO2827B1 (en) | Mineralocorticoid receptor antagonists and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |